Comment on “Impact of SGLT2i on Cardiovascular Outcomes Following Acute Myocardial Infarction With Heart Failure With Preserved Ejection Fraction: Propensity-Matched Registry Study”

Abstract

Get full access to this article

View all access options for this article.

References

Calcagno

Issa

Canova

, et al. Impact of SGLT2i on cardiovascular outcomes following acute myocardial infarction with heart failure with preserved ejection fraction: propensity-matched Registry Study. Angiology. 2026;77(7):875-882.

Wang

The role of SGLT-2 inhibitors in cardiovascular and renal protection. Curr Res Med Sci. 2025;4(1):41-50.

Maremmani

Ebrahimi

Centola

, et al. Association of sodium-glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis. Cardiovasc Diabetol. 2025;24(1):29.

Chen

Ran

Incidence and risk factors of heart failure with preserved ejection fraction in elderly patients with hypertension. BMC Cardiovasc Disord. 2024;24(1):742.

Sobolevskaya

Gvozdeva

Svirida

Filatova

AY.

Predictors of unfavorable progression and prognosis in patients with heart failure with preserved left ventricular ejection fraction. Med Herald South Russia. 2024;15(4):38-48.

Liang

Chang

Lai

, et al. Update on the efficacy and safety of sodium–glucose co-transporter 2 inhibitors in patients with chronic diseases: a systematic review and meta-analysis. Medicina. 2025;61(2):202.

Moledina

Rashid

Nolan

, et al. Addressing disparities of care in non-ST-segment elevation myocardial infarction patients without standard modifiable risk factors: insights from a nationwide cohort study. Eur J Prev Cardiol. 2022;29(7):1084-1092.